Acesso livre
Acesso livre

Infectologia Pediátrica

[Preprint] Risco de internação, doença grave e mortalidade por COVID-19 em crianças infectadas pelo SARS-CoV-2 na Alemanha – “A taxa de internação geral associada com infecção por SARS-CoV-2 foi de 35,9 por 10.000 crianças; a taxa de admissão em UTI foi de 1,7 por 10.000 e a taxa de casos fatais foi de 0,09 por 10.000.”

8 Dez, 2021 | 13:18h

Risk of Hospitalization, severe disease, and mortality due to COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany – medRxiv

Conteúdos relacionados:

Editorial: COVID-19 vaccines for children – “Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis”.

Review: Should children under 12 years of age be vaccinated against COVID-19?

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – “In total, 99.995% of children and young people with a positive SARS-CoV-2 test survived”.

Série de casos com 139 adolescentes e adultos jovens com suspeita de miocardite após vacina de mRNA mostrou que a maioria deles teve curso clínico leve e resolução rápida dos sintomas.

7 Dez, 2021 | 11:46h

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults – Circulation

Comunicado de imprensa: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association

Revisão de 4.470 casos de síndrome inflamatória multissistêmica em crianças nos EUA.

7 Dez, 2021 | 11:40h

Multisystem Inflammatory Syndrome in Children—United States, February 2020–July 2021 – Clinical Infectious Diseases

Conteúdos relacionados:

WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19.

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Relatório Clínico AAP | Tuberculose em crianças e adolescentes.

2 Dez, 2021 | 11:26h

Tuberculosis Infection in Children and Adolescents: Testing and Treatment – Pediatrics

EMA recomenda a aprovação da vacina da Pfizer-BioNTech para crianças de 5 a 11 anos.

26 Nov, 2021 | 12:06h

Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 – European Medicines Agency

Conteúdos relacionados:

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

What COVID vaccines for young kids could mean for the pandemic.

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.

FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.

 

Comentário no Twitter

 

M-A | Sintomas persistentes após infecção por SARS-CoV-2 entre crianças e jovens – “Melhor qualidade de estudo foi associada com menor prevalência de todos os sintomas, exceto perda de olfato e sintomas cognitivos.”

26 Nov, 2021 | 11:58h

Persistent symptoms following SARS-CoV-2 infection among children and young people: a meta-analysis of controlled and uncontrolled studies – Journal of Infection

Conteúdos relacionados:

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Long COVID: the physical and mental health of children and non-hospitalized young people after SARS-CoV-2 infection – one in seven children may still have symptoms 15 weeks after infection.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Cohort study: Risk factors for long covid in previously hospitalized children.

M-A: More than 50 long-term effects of COVID-19.

Diretriz provisória da OMS sobre a vacinação de crianças e adolescentes contra a COVID-19.

25 Nov, 2021 | 15:20h

Interim statement on COVID-19 vaccination for children and adolescents – World Health Organization

OMS emite diretrizes sobre o tratamento de crianças com síndrome inflamatória multissistêmica associada a COVID-19.

24 Nov, 2021 | 11:37h

Comunicado de imprensa: WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19 – World Health Organization

Diretriz: Living guidance for clinical management of COVID-19 – World Health Organziation

Conteúdos relacionados:

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Revisão sistemática | Vacinas para prevenção da diarreia causada por rotavírus.

24 Nov, 2021 | 11:06h

Vaccines for preventing rotavirus diarrhoea: vaccines in use – Cochrane Library

Resumo: Are rotavirus vaccines safe and effective in preventing rotavirus diarrhoea in infants and children? – Cochrane Library

Comentário: Vaccines for preventing rotavirus diarrhoea: an updated Cochrane review – Cochrane Library

Revisão | Prevenção de infecções emergentes em crianças.

23 Nov, 2021 | 15:33h

Prevention of Emerging Infections in Children – Pediatric Clinics of North America

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.